ArticleArthritis & rheumatology (Hoboken, N.J.)2025
Metabolic Syndrome, Adipokines, and Response to Advanced Therapies in Rheumatoid Arthritis.
Article in Arthritis & rheumatology (Hoboken, N.J.), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
8 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Therapeutic approaches for difficult-to-treat rheumatoid arthritis: a systematic literature review of current evidence.RMD open · 2026Pooled it
- Metabolic Complications in Autoimmune and Autoinflammatory Diseases: Pathophysiology, Clinical Implications, and Therapeutic Perspectives.Journal of clinical medicine · 2026Review
- The clinical significance of serum complement fibroblast growth factor 21 in patients with rheumatoid arthritis.BMC immunology · 2026Article
- Baseline body mass index and early functional recovery after first recorded advanced therapy in rheumatoid arthritis: a real-world cohort study.Rheumatology international · 2026Article
- Effects of age and sex on all-cause mortality among NHANES participants with metabolic syndrome and rheumatoid arthritis.BMC cardiovascular disorders · 2026Article
- Global prevalence of metabolic syndrome in patients with Rheumatoid arthritis: a systematic review and meta-analysis.BMC rheumatology · 2025Article
- Metabolic Consequences of Rheumatoid Arthritis.Arthritis care & research · 2025Review
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
objectiveWe determined if metabolic syndrome, its components, and adipokines (adiponectin, leptin, and fibroblast growth factor-21) were associated with response to advanced therapies among patients with rheumatoid arthritis (RA).
methodsThis study included participants with RA initiating either tumor necrosis factor inhibitor (TNFi) or non-TNFi biologic therapies from the Comparative Effectiveness Registry to study Therapies for Arthritis and Inflammatory Conditions (CERTAIN) cohort within the CorEvitas registry. Metabolic syndrome was defined according to the National Cholesterol Education Program Adult Treatment Panel III definition. Adipokines were assessed on stored samples from a subsample of responders and nonresponders (n = 200). The primary outcome was the achievement of a change as large as the minimal clinically important difference (MCID) for the Clinical Disease Activity Index (CDAI) at 6 months.
resultsAmong 2,368 participants, 687 (29%) had metabolic syndrome. Metabolic syndrome was associated with lower odds of achieving CDAI MCID (odds ratio [OR] 0.69, 95% confidence interval [CI] 0.56-0.86, P = 0.001) with a dose-dependent decrease in response rate according to the number of components present. Model fit was superior for metabolic syndrome compared with body mass index. Associations between metabolic syndrome and MCID achievement were similar between patients receiving TNFi (OR 0.65, 95% CI 0.49-0.87, P = 0.003) versus non-TNF therapies (OR 0.76, 95% CI 0.55-1.04, P = 0.08 [P for interaction = 0.49]). Adipokines were not associated with MCID achievement.
conclusionMetabolic syndrome is associated with lower response rates with the initiation of an advanced therapy in RA, with similar effects for both TNFi and non-TNFi agents. Adipokines were strongly associated with metabolic syndrome but were not associated with clinical response.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.